News & Events
Lead ACTH Antagonist CRN04894 (Cushing’s, CAH) Enters Phase 1 Study
This study will assess the safety and tolerability of single and multiple doses of CRN04894 and will measure the effect...
READ MORECRN04777 (Congenital Hyperinsulinism) Advances to Phase 1 Study
Phase 1 study of CRN04777, an oral, nonpeptide somatostatin receptor type 5 (SST5) agonist being developed as a treatment for...
READ MORE10th Annual SVB Leerink Global Healthcare Conference
Event Date: February 24–26, 2021
READ MORECrinetics Update 39th Annual J.P. Morgan Healthcare Conference
Webcast: Crinetics Pharmaceuticals’ Founder and CEO, Scott Struthers provides 2020 review and 2021 Plans at 39th Annual JP Morgan Healthcare...
READ MORECrinetics Announces 2021 Plans at J.P. Morgan Healthcare Conference
Scott Struthers, Ph.D., Founder & CEO of Crinetics, presented 2020 update and 2021 plans. Live webcast of the presentation may be...
READ MORE39th Annual J.P. Morgan Healthcare Conference
Event Date: January 11–14, 2021
READ MOREPodcast: Work Continues on New Drugs/Therapies for Pituitary Patients
We wondered how this critically important work for pituitary patients was affected by the pandemic. Dr. Struthers gives us an...
READ MOREEvercore ISI 3rd Annual HealthCONx Virtual Conference
Event Date: December 3, 2020
READ MORECrinetics Pharmaceuticals to Participate in December Investor Conferences
Dr. Scott Struthers and Dr. Alan Krasner present at 32nd annual Piper Sandler Healthcare Conference December 1st-3rd, 2020 Webcast available until...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.